Tag: Obinutuzumab

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By
Dr Moritz Fürstenau, University of Cologne, Germany
Trial
Phase 2, CLL2-BAAG
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 15:01

Obinutuzumab attenuates kidney decline in lupus nephritis

Presented By
Dr Brad Rovin, Ohio State University, OH, USA
Trial
Phase 2, NOBILITY
Conference
ASN 2023
Type
News article

28 November 2023 14:41

Triple-therapy improves PFS in fit, previously untreated CLL

Presented By
Prof. Barbara Eichhorst, University Hospital Cologne, Germany
Trial
Phase 3, GAIA/CLL13
Conference
EHA 2022
Type
News article

1 July 2022 11:43

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert
Dr Jennifer Woyach, Ohio State University, OH, USA
Trial
Phase 3, Alliance A041202
Conference
ASH 2021

3 February 2022 23:22
Afbeelding met persoon, person Automatisch gegenereerde beschrijving

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Expert
Dr. Talha Munir, Leeds Teaching Hospitals NHS Trust, UK
Trial
Phase 3, GLOW
Conference
ASH 2021

3 February 2022 23:15

ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia

Presented By
Dr. John Byrd, Ohio State University College of Medicine, USA
Trial
Phase 3, ELEVATE-TN
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 11:20

ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

Presented By
Dr Jeff Sharman, US Oncology Network, USA
Trial
Phase 3, ELEVATE-TN
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 13:50

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By
Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands
Trial
Phase 2, HOVON 139/GiVe
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 13:38

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By
Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands
Trial
Phase 2, GLOW
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 13:33

Lupus nephritis: new therapies on the horizon in 2020

Presented By
Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA
Conference
ACR 2020
Type
Peer-reviewed article

18 January 2021 10:54

Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL

Presented By
Dr Eugen Tausch, University of Ulm, Germany
Trial
CLL14
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 22:38

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By
Prof. Wojciech Jurczak, Jagiellonian University, Poland
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 17:13

Venetoclax-obinutuzumab combination elicits high response rates in CLL

Presented By
Dr Kirsten Fischer, University of Cologne, Germany
Trial
Phase 3, CLL14
Conference
EHA 2019
Type
Peer-reviewed article

9 June 2019 23:28
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com